Marketing of antipsychotic drugs targeted doctors of Medicaid patients, report says

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6633 (Published 2 October 2012)
Cite this as: BMJ 2012;345:e6633

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bob Roehr
  1. 1Washington, DC

Psychiatrists serving the 205 000 low income people covered by the Medicaid program in Washington, DC, disproportionately benefited from gifts and payments from pharmaceutical companies, compared with other local physicians, a study shows.

In addition, children covered by Medicaid, a principal focus of the program, were twice as likely as all Americans to be prescribed antipsychotic drugs. About one child in 10 was prescribed that class of drugs.

Those two associations were gleaned from an analysis of marketing data that pharmaceutical companies reported to the government of the District of Columbia under the AccessRx Act, which was passed in …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL